News ArchivesRead News
Austrian Biotech Firm's Parkinson's Vaccine
Wednesday July 30, 2014
The Local - An Austrian company has developed a potentially viable vaccine for early-stage Parkinson's disease. The treatment, which is designed to slow or even stop progression of the disease, has undergone a Phase I clinical trial, from which data was released on Thursday in New York.
The treatment is based on a candidate vaccine known as PD01A, which lowers levels of alpha-synuclein. This is a brain protein which is believed to play an important role in maintaining a supply of synaptic vesicles in presynaptic terminals, as well as helping to regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements.
The trial was conducted at the Confraternität Privatklinik Josefstadt in Vienna and involved up to 32 patients.
The preliminary results of the trial showed that the vaccine was well tolerated and safe, that it induced an immune response, and that the immune response appeared to be improving function.
"If you add all this together, I think we have the first evidence that would tell us that these findings are compatible with what we look for with disease modification," Achim Schneeberger, MD, chief medical officer of AFFiRiS, the Austrian pharmaceutical company developing the drug, told a press conference where the initial results were released.
AFFiRiS AG employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria where the vaccine was developed. In addition to its work on the Parkinson's vaccine, the company has been developing peptide vaccines for Alzheimer's disease and Atherosclerosis.
In part, the research was funded by the Michael J. Fox Foundation to the tune of $1.5 million (€1.12 million). The foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. Its founder, Michael J. Fox, is a well-known Canadian-American actor who is a high-profile victim of the disease.
(30 July 2014). The Local. Austrian Biotech Firm's Parkinson's Vaccine. http://www.thelocal.at/20140730/austrian-biotech-to-release-parkinsons-vaccine-data
Recent NewsOct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show
Aug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s